Cargando…
Remdesivir-induced bradycardia in a 26-year-old patient with COVID-19: a case report
PURPOSE: Remdesivir is the first line hospital treatment of the SARS-CoV-2 infection. Despite its widespread use during COVID-19 pandemic, a limited number of data, also conflicting, are available about the frequency of cardiological side-effects. Additionally, identification of patients who belong...
Autores principales: | Guziejko, Katarzyna, Talalaj, Jaroslaw, Chorazy, Monika, Groth, Monika, Moniuszko-Malinowska, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196856/ https://www.ncbi.nlm.nih.gov/pubmed/35701724 http://dx.doi.org/10.1007/s15010-022-01854-3 |
Ejemplares similares
-
Evaluation of Free Light Chains (FLCs) Synthesis in Response to Exposure to SARS-CoV-2
por: Gudowska-Sawczuk, Monika, et al.
Publicado: (2022) -
Remdesivir: Bradycardia: case report
Publicado: (2022) -
Remdesivir: Bradycardia: case report
Publicado: (2022) -
Pneumococcal meningitis and COVID-19: dangerous coexistence. A case report
por: Guziejko, Katarzyna, et al.
Publicado: (2022) -
Remdesivir-associated bradycardia
por: Ching, Patrick R, et al.
Publicado: (2021)